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Abstract
While hereditary cancer syndromes have been described and studied for centuries, the completion of the human genome project fueled accelerated progress in precision medicine due to the introduction of genetic testing in the 1990s, creating avenues for tailored treatments and medical
management options. However, genetic testing has not benefited everyone equitably, with nearly all of the published work based on individuals of non-Hispanic White/European ancestry. There remains a gap in knowledge regarding the prevalence, penetrance, and manifestations of
common hereditary cancer syndromes in the African-American population due to significant disparities in access and uptake of genetic testing.
This review summarizes the available literature on genetic testing for breast, colon, and prostate cancers in the African-American population
and explores the disparities in access to genetic testing between non-Hispanic White and African-American patients. This article also addresses
the barriers to genetic testing and discrepancies in the uptake of recommendations for hereditary cancer syndromes in the African-American
population when compared with non-Hispanic Whites. The review offers practice implications for many healthcare providers and demonstrates
gaps in the existing knowledge to be addressed in future studies to help eliminate the persisting health disparities faced by the African-American
population.
Key words: hereditary cancer syndromes; health disparities; African-American population; genetic testing; precision medicine.

Implications for Practice
Genetics and genetic testing have been historically used against marginalized individuals in healthcare settings. Gaining trust from
historically excluded populations such as African Americans is pertinent for clinicians/healthcare providers to achieve equitable health
outcomes. This review summarizes the existing gaps in access to and uptake of genetic testing among African-American individuals,
allowing healthcare providers to reflect on implicit and explicit biases that persist in the field of genetics. Since barriers to access exist at
different entry points to care for African-American individuals, this article provides recommendations to address these barriers as well as
outlines facilitators to increase access.

Introduction
Hereditary cancer syndromes have been described since the
1800s, prompted in part by increased cancer prevalence observed in prominent families such as those of Napoleon and
Madame Z.1 Genetic testing for many of these syndromes has
been available since the 1990s. However, 30 years later, due
to significant disparities in genetic testing access and uptake,
relatively little is known about the unique prevalence, manifestations, and penetrance of these inherited syndromes in the
non-Hispanic (NH) Black/African-American population (for
the purpose of this article, we use African American as an
inclusive term for individuals of African descent as well as
individuals who identify as Black, with or without African
lineage). Since the advent of genetic testing, facilitated by
the completion of the Human Genome Project, most published data in this area have been based on populations of

European ancestry.2 The 2-fold purpose of this review is to
(1) summarize the available literature on disparities in genetic evaluation for hereditary breast, colorectal, and prostate
cancer syndromes in the African-American population in the
US and (2) describe further areas of study and outreach in this
medically underserved population. We also address barriers
to genetic testing and highlight interventions to improve the
utilization of cancer genetics services in this population.

Hereditary Breast Cancer
Breast cancer is the second most common cancer among
African-American women; 1 in 9 African-American women,
compared with 1 in 8 NH White (NHW) women, will be
diagnosed with breast cancer.3 Incidence rates of breast cancer
under the age of 45 years are 16% higher among AfricanAmerican women than among NHW women (incidence rate
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testing when it was offered (58% vs 71%; OR, 0.54, 95%
CI, 0.34-0.85). Some of the lack of uptake may be due to a
lack of health insurance coverage.20 However, in a subset of
this study’s population, African-American women who were
more recently diagnosed with breast cancer (<1 year) were
more amenable to genetic testing than those with a more remote diagnosis (>1 year before a genetic evaluation) (71% vs
66%; OR, 1.58, 95% CI, 1.10-2.29). Because genetic testing
can inform immediate medical management options for some
patients, this difference in uptake between recently and remotely diagnosed groups highlights the importance of offering a timely genetic assessment.
When genetic testing is offered, the acceptance rate for such
testing can influence medical management and cascade testing
for family members. Halbert et al (2006)21 evaluated acceptance rates for BRCA1/2 test results among African-American
women while considering cultural factors such as communalism and spiritual beliefs in this population. Among women
who were at an increased risk for carrying a BRCA1/2 mutation, less than half completed pre-genetic testing education
and counseling, and only about one-fifth of the overall sample
received test results.21 African-American women who were
less certain about their risk of developing breast cancer were
3 times more likely to receive BRCA1/2 test results compared
with women who were more certain about their risk.21 Such
discrepancies in the receipt of results based on risk certainty
may be improved by emphasizing the utility of testing for both
the individual and her family members. Testing uptake may
be increased by ensuring informed decision making, including
a thorough understanding of relative risks, the testing process, and the advantages and disadvantages of testing.17 In
particular, discussion of protections against genetic discrimination, such as the Genetic Information Nondiscrimination
Act (GINA), should be emphasized.
Differences in the uptake of genetic testing and counseling
by African-American women with breast cancer––with earlier
studies showing underutilization18,19,21 and more recent data14
showing no significant differences compared with NHW
women––may be explained by an increase in the availability
and accessibility of such services as well as their decreasing
cost. Equitable access to genetic services, including increased
genetic education and awareness as well as appropriate referrals and insurance coverage, is key to the use of these services
by African-American women.8

Hereditary Colorectal Cancer
Although preventable and treatable with early detection
screening, colorectal cancer (CRC) disproportionally affects
the African-American community. CRC is the third most
common cancer in African Americans and the third most
common cause of cancer-related death in African-American
men and women.3 Incidence rates of CRC are 19%-24%
higher in African Americans than in NH Whites, with AfricanAmerican men having disproportionately higher rates of
CRC-related mortality than any other racial/ethnic group.22
CRC tends to present at earlier ages in African Americans
than in NHWs, with African Americans being 4 years
younger at presentation compared with NH Whites (P
= .0012) and often presenting with a more advanced
disease.23,24 Although early age of diagnosis can indicate
a hereditary cause of cancer, reports are conflicting as to
whether rates of hereditary CRC syndromes are higher in
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ratio [IRR] = 1.16; 95% confidence interval [CI] = 1.10-1.23),
and mortality from breast cancer is 42% higher in AfricanAmerican patients than in NHW patients.4 The causes of these
differences in outcomes are multifactorial and are partly attributable to a more advanced stage at diagnosis and unfavorable tumor characteristics such as triple-negative disease, high
tumor grade, and inflammatory carcinoma.3-7
Genetic counseling and testing can identify hereditary
cancer risks that have valuable implications for prevention
and treatment. In the CARRIERS consortium, a group of
over 28 000 participants, the prevalence rate for a pathogenic variant (PV) in one of the 12 breast cancer susceptibility
genes was 5.65% for African-American women with breast
cancer compared to 5.06% for NHW women with breast
cancer (P = .12).8 Rates of genetic testing for individuals who
meet guidelines for BRCA1/2 testing remain sub-optimal
across all populations despite access and insurance coverage.9
However, compared with other races and ethnicities, AfricanAmerican patients with breast cancer have lower rates of
referral for genetic evaluation.10-15 Additionally, AfricanAmerican women with breast cancer are more likely than
NHW women to have PVs in BRCA2 (1.80% vs 1.24%; P =
.005) and PALB2 (1.01% vs 0.40%; P < .001).8 Ademuyiwa
et al (2019)11 found that 41.2% of African-American women
who were eligible for BRCA1/2 mutation testing according
to National Comprehensive Cancer Network (NCCN) guidelines did not receive it as part of their routine care. Healthcare
providers were 16 times less likely to discuss genetic testing
with African Americans than with their NHW counterparts.16 Similarly, Armstrong et al (2005)10 found that African
Americans were significantly less likely than NH Whites with
comparable cancer family histories to be referred for genetic
counseling (odds ratio [OR], 0.22). McCarthy et al (2016)13
reported that African-American women’s physicians were less
likely to recommend BRCA1/2 testing (OR, 0.38; 95% CI,
0.32-0.45; P < .001), a difference that persisted after adjustment for mutation risk, clinical factors, sociodemographic
characteristics, and attitudes toward testing.
Despite the low referral rate, studies demonstrate that
African-American patients with breast cancer are interested in
genetic testing.6,14,17 Compared with NHW women, AfricanAmerican women had more positive attitudes about the benefits of genetic testing but lower levels of knowledge about
genetic testing for breast cancer risks.6 Peterson et al (2020)14
found that, although genetic counseling referral rates differed
by race, uptake of genetic counseling services among AfricanAmerican patients who were referred was not significantly
different than uptake among NHW women. Therefore, low
levels of genetic evaluation in the African-American population are less likely to be attributable to a lack of interest.
Another important metric is the uptake of genetic testing
by African-American women with breast cancer when offered
by genetic counselors. Peters et al18 found in 2004 that, after
adjusting for awareness, African-American patients were less
likely than NHW women to endorse the potential benefits of
genetic testing due to concerns about the use of genetic tests
for racial discrimination and the establishment of racial hierarchy (OR, 2.15, 95% CI, 0.15-4.03), which highlights the
mistrust of the healthcare system. Even after minimizing test
cost and other barriers to accessing genetic testing services
among African-American women, Susswein et al (2008)19
found that African-American women were significantly less
likely than their NHW counterparts to pursue BRCA1/2
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Hereditary Prostate Cancer
Prostate cancer is the most common cancer diagnosis and
the second most common cause of cancer-related death in
African-American men. It occurs more frequently and at an
earlier age in African Americans than in NH Whites. The
prevalence of prostate cancer in African-American men is 1
in 7 and the average age at diagnosis is 63 years, compared
with a prevalence of 1 in 9 and an average age at diagnosis of
66 years in NHW men.3 African-American men are also more
likely to be diagnosed with aggressive disease (rate ratio 3.084.91).34 Although the mortality rate from prostate cancer
has markedly decreased in recent years among both African
Americans and NH Whites (and decreased more quickly for
African Americans than for NH Whites between 2006 and
2015 [3]), 5-year mortality for African Americans remains
2.5-fold higher than for NHW men.35 The higher incidence
and mortality for African-American men with prostate cancer
compared with their NHW counterparts persists even after
accounting for socioeconomic factors.36,37

Familial prostate cancer has been recognized for decades,
but a lack of identified predisposition genes has historically
limited the use of genetic testing for this condition in both
African Americans and the general population. The 2017
Philadelphia Prostate Cancer Consensus Conference provided the impetus to expand germline testing in the US to
all men with metastatic castrate-resistant prostate cancer.38
These guidelines recommended using the same criteria for
genetic testing in African-American men as in other men until
additional data on molecular differences in prostate cancer in
African-American men are available to guide more-tailored
medical management. Due to a continuing absence of data,
this recommendation did not change in a 2019 guideline
update.39
Although current reports on the uptake and practices
of genetic testing specific to the African American prostate
cancer population are lacking, earlier studies have attempted
to address this question. In a 2002 study of interest in genetic
testing for prostate cancer predisposition among 320 AfricanAmerican men,40 an overwhelming majority of subjects (87%)
responded that they would like to have a (then theoretical)
genetic test for hereditary prostate cancer. This response did
not vary by age, education, or family history. Additional reports from the African-American Hereditary Prostate Cancer
study (also conducted before the expansion of the guidelines
on germline testing for prostate cancer susceptibility) demonstrated low levels of prostate cancer-specific knowledge
and low levels of prostate cancer screening in this high-risk
cohort. In this group of African-American men who had at
least 4 family members with prostate cancer, rates of digital
rectal examination (DRE) and prostate-specific antigen (PSA)
screening were lower than those in the general AfricanAmerican population (DRE 35% vs 45%; PSA 45% vs
65%).41,42
Although the literature on the population-specific incidence
rate of the BRCA1/2 mutation is scarce, a preliminary study
by Petrovics et al (2016)43 identified pathogenic mutations and
variants of uncertain significance (VUSs) in 7.3% of AfricanAmerican patients with prostate cancer versus 2.2% of NHW
patients. It is known that, compared with non-carriers, carriers of germline BRCA1/2 mutations can present with more
aggressive disease and have a higher risk of recurrence and
prostate cancer-specific mortality. Moreover, therapeutic clinical trials are increasingly using germline BRCA1/2 mutation
carrier status to determine participant eligibility. Further research is therefore needed on the incidence and prevalence of
inherited prostate cancer susceptibility in African-American
men compared with NHW men. In addition to its implications for familial cancer risks among African-American families, this knowledge could be pertinent to reducing disparities
in prostate cancer treatment, which could in turn lead to a
reduction in prostate cancer mortality rates among AfricanAmerican men.

Barriers to Testing and Interventions
Access to genetic counseling and appropriate genetic testing
can have far-reaching implications in improving health and
reducing health-related disparities in medically underserved
populations. Although testing for multi-gene hereditary
cancers is becoming increasingly accessible, if access to appropriate pre- and post-test genetic counseling is limited,
medically underserved patients may face barriers to the

Downloaded from https://academic.oup.com/oncolo/article/27/4/285/6542925 by Thomas Jefferson University user on 26 April 2022

African Americans than in the NHW population. Hereditary
non-polyposis colorectal cancer (HNPCC)—also known as
Lynch syndrome—is the most common hereditary CRC
syndrome among high-risk African Americans. Recent analysis of a large, nonselective, ancestrally diverse database of
over 30 000 subjects has suggested that the prevalence of
HNPCC is significantly higher in people of African ancestry
(1 in 299) than in those of NHW (1 in 518) or Hispanic/
Latino ancestry (1 in 634).25
Given the higher prevalence of HNPCC among African
Americans, access to genetic counseling and genetic testing
can significantly improve mortality and reduce late-stage
diagnoses.26,27 In a study of patients referred to a high-risk
CRC clinic, African Americans’ lack of knowledge of family
cancer history was cited as a factor limiting these individuals’ access to genetic testing.28 Prior studies have reported
that family-history gathering and test interpretation may also
be more complicated in the African-American population.
Kupfer et al (2006)28 found that among patients referred to
their clinic, 18.9% of African Americans did not know their
family history in their paternal lineage compared to 6.5% of
NH Whites (P ≤ .05). However, a more recent study suggested
that only about one-third (31.1%) of the general population
in the US tends to have a thorough knowledge of their family
history information.29
Abnormal immunohistochemistry (IHC) results on colon
tumor testing are another pathway to referral for genetic
testing. Studies show a similar rate of mismatch repair deficiency on IHC testing of colon tumors in African-American
and NHW populations, and many cancer centers have introduced universal screening for HNPCC for all colon cancers.30-32 Muller et al (2018)33 found a lower rate of provider
referral for genetic evaluation among African Americans
compared with NH Whites, even for those with abnormal
IHC results (17% vs 21% in NHW, P = .02). Although there
was no between-group difference in attendance at genetics
appointments, the uptake rate for genetic testing was lower
among African Americans (6% vs 11% in NH Whites, P =
<.01). This pattern of decreased rates of referral, similar rates
of appointment uptake, and decreased rates of testing uptake
for African Americans compared with NH Whites merits further study.
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Rogers et al found that educational levels, unfavorable
attitudes toward research, lack of healthcare access, and
the legacy of medical mistrust stemming from the Tuskegee
Syphilis Study and perpetuated by lived experience were
key barriers to the uptake of prostate cancer genetic testing
and research participation by African-American men.48 A report on medical mistrust as a barrier to the uptake of genetic services47 concluded that “…African Americans were less
likely to endorse health benefits of genetic testing and more
likely to believe that the government would use test results to
label groups as inferior.”
These perceived barriers can potentially be eliminated
through education–focused interventions that are also
culture-specific.42 When aiming to reduce inequities in cancer
outcomes and screening among underserved and socially
vulnerable populations, culturally tailored health educational interventions are a promising approach for the genetic
evaluation space. For instance, Pal and colleagues (2010)49
found that culturally target visual aids married to phonebased genetic counseling was improved inherited breast and
ovarian cancer knowledge among young African-American
women with invasive breast cancer. However, some interventions to improve patient education about genetic services
have proven more effective than others. As noted above,
Halbert et al (2006)21 found that culturally tailored versus
standard genetic counseling resulted in no difference in the
uptake of genetic testing by African-American patients with
breast cancer. Psychoeducation intervention is an approach
that has been investigated to improve uptake of genetic
services in breast cancer survivors.50,51 To eradicate barriers to genetic services referral and uptake among African
Americans, further development of targeted interventions
to increase awareness and trust while reducing stigma is
warranted.
Other interventions to facilitate genetic services uptake
have been studied in African-American and other medically
underserved populations. The Prostate REACH study was an
intervention for 64 medically underserved men, a majority
of whom (n = 37) were African American. Most participants
valued the patient navigator services and assistance with insurance barriers that the study offered. Community partnerships and organizational relations were fundamental to the
program’s success. However, despite using a broad range of
community- and media-based recruitment methods, recruitment of underserved men was difficult for this project and
others.52,53 Despite these challenges, partnership with community leaders and groups remains a critical component of
programs to decrease health disparities.
Alternative education methods may be another effective
intervention, particularly to address geographical disparities.
Computer-assisted methods, video methods, and possibly
group education may be approaches to increase genetic education and reduce out-of-pocket expenses.54 Even before the
COVID-19 pandemic, genetic counseling via telemedicine was
well established,54 including audio-only technology, and is not
inferior to in-person counseling; thus, telemedicine can play a
key role in reducing barriers to genetic counseling services.55,56
Major genetic testing companies have aided in the collection
of DNA specimens for testing through in-home phlebotomy
programs and postage-paid saliva kits. Although these interventions were not used specifically to facilitate uptake among
African Americans, they could be constructed to target this
medically underserved population.
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appropriate interpretation of results, potentially widening the
gap in their treatment or medical management when compared with populations that are not underserved.
Ndugga-Kabuye et al (2019)44 found that AfricanAmerican patients with cancer who were offered genetic
testing for the BRCA1/2 and HNPCC genes were more
likely than their NHW counterparts to be identified as
having a VUS (18.8% vs 6.1%; P < .001). This disparity
persisted among African-American patients when compared
to NHW patients without a personal history of cancer, who
were offered genetic testing for the BRCA1/2 and HNPCC
genes based on their family history (12.3% vs 5.8%; P <
.001).44 VUS results can be challenging both for patients
and for healthcare providers who are not genetics specialists, as they can represent either a benign human variation
or a change causing an increased risk for cancer. When mismanaged, VUS results can lead to potentially unnecessary
and invasive surveillance, surgery, or misinformed family
planning.
The largest population allele frequency database, the
Genome Aggregation Database (gnomAD) contains 141,456
unrelated individuals from several large-scale sequencing projects and is routinely used to help with variant interpretation
and classification. This database lacks ancestral diversity, with
58.2% of individuals represented being of European (Finnish;
non-Finnish European; Ashkenazi Jewish) ancestry versus
8.8% African or African-American ancestry. Structural barriers may exist for equitable research participation leading to
excessive homogeneity of source samples. This gap in knowledge creates barriers to variant interpretation for AfricanAmerican patients, leaving their genetic test results more
prone to mismanagement.
In addition to the lack of data on the incidence and prevalence of gene mutations in African-American patients, genetic referral rates for African-American patients lag behind
those of NHW patients, despite studies showing that AfricanAmerican cancer patients are interested in this information. The prevalence of systemic and implicit biases within
healthcare organizations continues to cause healthcare providers to act as gatekeepers for genetic testing, resulting in
lower referral rates for genetic services in African Americans
compared with NH Whites.
One common misperception that may affect referral rates is
that genetic evaluation is not affordable for patients who are
uninsured or underinsured. African-American patients consistently have lower insurance benefits than NHW patients,45
and patients with Medicaid have been found to receive less
genetic counseling than patients who are privately insured,46
despite the increasing accessibility of multi-gene panel testing,
which can be performed for an out-of-pocket cost of about
$150 to $250. In addition, the major companies offering
genetic testing for hereditary cancer syndromes have patient
assistance programs or payment plans to help reduce or eliminate the cost associated with genetic testing.
Although uptake of genetic counseling appointments does
not appear to differ by race or ethnicity, the literature suggests that uptake of genetic testing does. This may be related
to the cost of genetic testing, as mentioned above, or maybe
affected by mistrust of the medical community in the AfricanAmerican population. Individual-level inhibitors to the completion of genetic testing for hereditary cancer risk may also
stem from African Americans’ knowledge, attitudes, beliefs,
awareness, and perceptions.47
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Recommendations and Conclusion
The following are key recommendations based on this review:

As precision medicine is rapidly incorporated into every
area of medicine, genetic testing will continue to have practice implications for both patients and healthcare providers.
Identifying and addressing knowledge gaps in this area
through culturally literate communication and education
tactics can facilitate genetic testing uptake. These efforts will
contribute to eliminating the persistent health disparities

plaguing African-American communities who continue to
suffer disproportionately from breast, colorectal, and prostate cancers.
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